Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Medoderm GmbH has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is being examined by 1 distinct examiner within 1 distinct art unit. The company's active patent prosecution is currently limited to this single technical interaction. This focus on 1 pending office action indicates a specific priority within the company's biotechnology portfolio.
SCHACHERMEYER, SAMANTHA LYNN is the busiest examiner for the portfolio, with 1 pending office action. This examiner is responsible for the only pending action listed for the company. Prosecution success is currently dependent on the resolution of this matter by this specific examiner. Practitioners should evaluate the examiner's past decisions within the 1 assigned art unit to better inform their approach to this pending action.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BERRIOS, JENNIFER A | 1 | 37.1% | +49.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17601783 | LIQUID COMPOSITION FOR INFLUENCING THE MICROBIOTA ON A SUBJECT'S SKIN COMPRISING CHITOSAN | BERRIOS, JENNIFER A | 11d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17601783 | LIQUID COMPOSITION FOR INFLUENCING THE MICROBIOTA ON A SUBJECT'S SKIN COMPRISING CHITOSAN | BERRIOS, JENNIFER A | 11d overdue |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17601783 | LIQUID COMPOSITION FOR INFLUENCING THE MICROBIOTA ON A SUBJECT'S SKIN COMPRISING CHITOSAN | BERRIOS, JENNIFER A | 1613 | §103§112 | Final Rejection | 11d overdue | Pending | Oct 06, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMedoderm GmbH has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jennifer A Berrios has the most, with 1 of Medoderm GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
